A MESSAGE FROM THE CHAIMAN
Finally, the Company and its Board go into the new financial year with a high degree of
confidence that Veyonda® will be the so-called “missing link” needed to enhance other
existing treatments for cancer and bring hope to those suffering from this disease.
I am hopeful that our shareholders who have had the faith to invest in Noxopharm shall
continue to do so and in doing this, so reap the rewards of their investment.
Yours sincerely,
Fred Bart, Chairman
ASCO thoughts, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
